secwatch.observer — SEC 8-K summary
======================================

Issuer:     Clarus Therapeutics Holdings, Inc. (—)
CIK:        0001817944
Form:       8-K
Filed at:   2022-10-31T23:59:59+00:00
Accession:  0001213900-22-067678
Event type: m_and_a
Sentiment:  negative
Materiality: 1.00
Item codes: 1.01, 2.01, 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Clarus Therapeutics sells JATENZO® assets to Tolmar for $7.25M upfront plus royalties; board resigns, CEO terminated
--------------------------------------------------------------------------------

- Asset purchase agreement with Tolmar, Inc. for $7.25M upfront plus 6-10% royalties on net sales and milestones up to $7M.
- Sale completed Oct 27, 2022 after Bankruptcy Court approval; total consideration depends on future sales.
- Board members John Amory, Elizabeth Cermak, Kimberly Murphy, Mark Prygocki, Alex Zisson resign effective Oct 31.
- CEO Robert Dudley terminated effective Oct 31; CAO/CFO Steven Bourne and CCO Frank A. Jaeger terminated Nov 14.
- Trading in Clarus securities during Chapter 11 is highly speculative; company urges extreme caution.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1817944/000121390022067678/0001213900-22-067678-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1817944/000121390022067678/ea167801-8k_clarusthera.htm
  HTML page:      https://secwatch.observer/filing/0001213900-22-067678

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer